阅读说明：本技术 一种治疗鼻炎的药物或日化用品 (Medicine or daily chemical product for treating rhinitis ) 是由 苏琛 罗霞 张涛 宋怡 杨欣怡 罗舒 于 2020-06-05 设计创作，主要内容包括：本发明涉及一种治疗鼻炎的药物或日化用品。具体提供了一种由下述重量份数的原料药组成的药物组合物：丁香6～12份,鹅不食草6～12份,羌活3～9份,佛手6～12份,薄荷3～9份,桔梗3～9份,川芎3～9份,灵芝3～9份。本发明还提供了以该药物组合物为活性成分制得的鼻炎膏,该鼻炎膏能够有效缓解过敏性鼻炎,急性、慢性鼻炎,鼻窦炎及感冒导致的喷嚏、鼻塞、流涕等症状。将该鼻炎膏涂抹在鼻腔和鼻翼周围,可长时间发挥缓释作用,达到经皮吸收作用,从而发挥药效,明显提高了患者接受程度。以本发明提供的药物组合物为活性成分,加上药学上可接受的或日化领域常用的辅料,可以制得治疗鼻炎,以及鼻炎引起的喷嚏、鼻塞、流涕等症状的药物或日化用品,应用前景广阔。(The invention relates to a medicine or daily chemical product for treating rhinitis. In particular to a pharmaceutical composition which is composed of the following raw material medicines in parts by weight: 6-12 parts of clove, 6-12 parts of centipeda minima, 3-9 parts of notopterygium root, 6-12 parts of fingered citron, 3-9 parts of mint, 3-9 parts of platycodon grandiflorum, 3-9 parts of ligusticum wallichii and 3-9 parts of lucid ganoderma. The invention also provides rhinitis ointment prepared by taking the pharmaceutical composition as an active ingredient, and the rhinitis ointment can effectively relieve symptoms such as sneeze, nasal obstruction, watery nasal discharge and the like caused by allergic rhinitis, acute rhinitis, chronic rhinitis, nasosinusitis and cold. The rhinitis ointment is smeared around the nasal cavity and nasal wings, can exert a slow release effect for a long time, achieves a percutaneous absorption effect, exerts a drug effect and obviously improves the acceptance degree of patients. The pharmaceutical composition provided by the invention is taken as an active ingredient, and auxiliary materials which are acceptable in pharmacy or commonly used in the daily chemical field are added, so that the medicine or daily chemical product for treating rhinitis and symptoms such as sneeze, nasal obstruction, rhinorrhea and the like caused by rhinitis can be prepared, and the application prospect is wide.)

1. A pharmaceutical composition characterized by: the pharmaceutical composition is composed of the following raw material medicines in parts by weight: 6-12 parts of clove, 6-12 parts of centipeda minima, 3-9 parts of notopterygium root, 6-12 parts of fingered citron, 3-9 parts of mint, 3-9 parts of platycodon grandiflorum, 3-9 parts of ligusticum wallichii and 3-9 parts of lucid ganoderma.

2. The pharmaceutical composition of claim 1, wherein: the pharmaceutical composition is composed of the following raw material medicines in parts by weight: 6-9 parts of clove, 6-9 parts of centipeda minima, 3-6 parts of notopterygium root, 6-9 parts of fingered citron, 6-9 parts of mint, 6-9 parts of platycodon grandiflorum, 6-9 parts of ligusticum wallichii and 3-9 parts of lucid ganoderma;

preferably, the pharmaceutical composition is composed of the following raw material medicines in parts by weight: 9 parts of clove, 9 parts of centipeda minima, 3 parts of notopterygium root, 9 parts of fingered citron, 6 parts of mint, 6 parts of platycodon grandiflorum, 6 parts of ligusticum wallichii and 3 parts of ganoderma lucidum.

3. A process for preparing a pharmaceutical composition according to any one of claims 1 to 2, wherein: the method comprises the following steps:

weighing the raw material medicine of any one of claims 1-2, adding a solvent, extracting, filtering, centrifuging, and taking supernatant to obtain the traditional Chinese medicine.

4. The method of claim 3, wherein: the solvent is oil, preferably white oil;

the mass-volume ratio of the pharmaceutical composition to the solvent is 1: (5-15) g/mL, preferably 1: 10 g/mL;

the extraction mode is frying or oil immersion, and preferably frying; the extraction times are 1-3 times, preferably 2 times; the extraction time is 10-20 min/time, preferably 15 min/time.

5. A medicine for treating rhinitis is characterized in that: the medicine is a preparation prepared by taking the pharmaceutical composition of any one of claims 1-2 as an active ingredient and adding pharmaceutically acceptable auxiliary materials.

6. The medicament of claim 5, wherein: the preparation is capsule, tablet, pill, granule, oral liquid, paste, spray, liniment or drop, preferably paste.

7. The medicament according to claim 5 or 6, characterized in that: the pharmaceutically acceptable auxiliary materials comprise a thickening agent, a humectant, water and a surfactant;

preferably, the thickening agent is carbomer 940, the humectant is one or more of hyaluronic acid, butanediol, glycerol and allantoin, the surfactant is a nonionic surfactant, and the nonionic surfactant is preferably one or more of SEPLGEL 305 and triethanolamine.

8. The medicament of claim 7, wherein: the medicine comprises the following raw materials in parts by weight: 15 parts of a medicinal composition, 0.8 part of a thickening agent, 6.3 parts of a humectant, 76.55 parts of water and 1.35 parts of a surfactant;

preferably, the medicine comprises the following raw materials in parts by weight: 15 parts of a pharmaceutical composition, 9400.8 parts of carbomer resin, 0.1 part of hyaluronic acid, 3 parts of butanediol, 3 parts of glycerol, 0.2 part of allantoin, 76.55 parts of water, 3051 part of SEPLGEL and 0.35 part of triethanolamine.

9. A daily chemical article characterized by: the daily chemical product is prepared by taking the pharmaceutical composition as defined in any one of claims 1-2 as an active ingredient and adding auxiliary materials commonly used in the daily chemical field;

preferably, the daily chemical product is a cosmetic; more preferably, the cosmetic is a spray, lotion, liniment, ointment, cream, essence, essential oil, emulsion, powder, film or patch.

10. Use of the pharmaceutical composition according to any one of claims 1 to 2 for the preparation of a medicament or daily chemical product for the treatment of rhinitis, or for the preparation of a medicament or daily chemical product for the treatment of sneezing, nasal congestion, or rhinorrhea; preferably, the rhinitis is allergic rhinitis, acute rhinitis, chronic rhinitis or sinusitis; the sneeze, nasal obstruction or nasal discharge is caused by allergic rhinitis, acute rhinitis, chronic rhinitis, sinusitis or cold.

Technical Field

The invention belongs to the field of medicines, and particularly relates to a medicine or daily chemical product for treating rhinitis.

Background

Rhinitis refers to inflammation of nasal mucosa and submucosal tissues, manifested as congestion or edema, and symptoms of nasal obstruction, clear watery nasal discharge, nasal itching, throat discomfort, cough and the like often appear in patients. Rhinitis is a frequently encountered disease and a common disease in people, is mostly expressed as long in disease course and easy to relapse, and brings inconvenience to life and study of patients. Rhinitis can be classified into allergic rhinitis (also called allergic rhinitis), acute rhinitis, chronic rhinitis, sinusitis, and the like.

At present, no special specific medicine is available for treating rhinitis, and common anti-inflammatory medicines and symptomatic treatment are mostly used. At present, nasal orifice clearing products in the market are mainly nasal obstruction agents, nasal inhalation agents and nasal spray agents, and in the administration process of the products, the nasal cilia can clear foreign bodies, so that the administration difficulty is increased. Moreover, some products contain ephedrine or hormones, which can relieve rhinitis symptoms, but frequent use can cause "rebound", and more severe nasal obstruction; if the medicine is used for a long time, the medicine dependence is also generated. In addition, the drugs for treating acute and chronic rhinitis on the market are not satisfactory in terms of efficiency, persistence and recurrence rate. Therefore, there is a need to develop a medicine for treating rhinitis, which has higher effective rate, higher persistence and less toxic and side effects.

In addition, although the cosmetics on the market are various in types, the effects of most cosmetics are cleaning, maintaining and beautifying. There are few cosmetics that can effectively treat rhinitis. If the cosmetics capable of effectively treating rhinitis can be prepared, the treatment purpose can be easily realized in daily life, and the cosmetics have good market prospect.

Disclosure of Invention

The invention aims to provide a medicament or daily chemical product for treating rhinitis, which has higher effective rate and less toxic and side effects.

The invention provides a pharmaceutical composition, which consists of the following raw material medicines in parts by weight: 6-12 parts of clove, 6-12 parts of centipeda minima, 3-9 parts of notopterygium root, 6-12 parts of fingered citron, 3-9 parts of mint, 3-9 parts of platycodon grandiflorum, 3-9 parts of ligusticum wallichii and 3-9 parts of lucid ganoderma.

Further, the pharmaceutical composition is composed of the following raw material medicines in parts by weight: 6-9 parts of clove, 6-9 parts of centipeda minima, 3-6 parts of notopterygium root, 6-9 parts of fingered citron, 6-9 parts of mint, 6-9 parts of platycodon grandiflorum, 6-9 parts of ligusticum wallichii and 3-9 parts of lucid ganoderma;

preferably, the pharmaceutical composition is composed of the following raw material medicines in parts by weight: 9 parts of clove, 9 parts of centipeda minima, 3 parts of notopterygium root, 9 parts of fingered citron, 6 parts of mint, 6 parts of platycodon grandiflorum, 6 parts of ligusticum wallichii and 3 parts of ganoderma lucidum.

The invention also provides a method for preparing the pharmaceutical composition, which comprises the following steps:

weighing the above raw materials, adding solvent, extracting, filtering, centrifuging, and collecting supernatant.

Further, the solvent is an oil, preferably white oil;

the mass-volume ratio of the pharmaceutical composition to the solvent is 1: (5-15) g/mL, preferably 1: 10 g/mL;

the extraction mode is frying or oil immersion, and preferably frying; the extraction times are 1-3 times, preferably 2 times; the extraction time is 10-20 min/time, preferably 15 min/time.

The invention also provides a medicine for treating rhinitis, which is a preparation prepared by taking the medicine composition as an active ingredient and adding pharmaceutically acceptable auxiliary materials.

Further, the preparation is capsule, tablet, pill, granule, oral liquid, paste, spray, liniment or drop, preferably paste.

Further, the pharmaceutically acceptable auxiliary materials comprise a thickening agent, a humectant, water and a surfactant;

preferably, the thickening agent is carbomer 940, the humectant is one or more of hyaluronic acid, butanediol, glycerol and allantoin, the surfactant is a nonionic surfactant, and the nonionic surfactant is preferably one or more of SEPLGEL 305 and triethanolamine.

Further, the medicine comprises the following raw materials in parts by weight: 15 parts of a medicinal composition, 0.8 part of a thickening agent, 6.3 parts of a humectant, 76.55 parts of water and 1.35 parts of a surfactant;

preferably, the medicine comprises the following raw materials in parts by weight: 15 parts of a pharmaceutical composition, 9400.8 parts of carbomer resin, 0.1 part of hyaluronic acid, 3 parts of butanediol, 3 parts of glycerol, 0.2 part of allantoin, 76.55 parts of water, 3051 part of SEPLGEL and 0.35 part of triethanolamine.

The invention also provides a daily chemical product which is prepared by taking the pharmaceutical composition as an active ingredient and adding auxiliary materials commonly used in the daily chemical field;

preferably, the daily chemical product is a cosmetic; more preferably, the cosmetic is a spray, lotion, liniment, ointment, cream, essence, essential oil, emulsion, powder, film or patch.

The invention also provides the application of the pharmaceutical composition in preparing a medicament or a daily chemical product for treating rhinitis, or in preparing a medicament or a daily chemical product for treating sneezing, nasal obstruction or rhinorrhea; preferably, the rhinitis is allergic rhinitis, acute rhinitis, chronic rhinitis or sinusitis; the sneeze, nasal obstruction or nasal discharge is caused by allergic rhinitis, acute rhinitis, chronic rhinitis, sinusitis or cold.

The nose is the lung orifice, and when exogenous pathogenic factors attack the exterior and the exterior defense is blocked, the flow of body fluid and qi is obstructed, qi stagnation and fluid coagulation appear, and obstruction in the nose orifice causes nasal obstruction and rhinorrhea. In the formula of the pharmaceutical composition, notopterygium root is pungent, bitter and warm in activity and has the effects of dispelling cold, dispelling wind, removing dampness and relieving pain, and notopterygium root is a monarch drug which can externally disperse pathogenic qi, remove dampness and dissolve turbidity and drive pathogenic qi to eliminate causes. Platycodon root, radix Platycodi is bitter, pungent and mild. Has effects in dispersing lung qi, eliminating phlegm, and expelling pus; herba Menthae has effects of refreshing head and eyes, and relieving nasal obstruction; the centipeda minima has the effects of relieving stuffy nose and relieving cough and detoxifying, and is mainly used for treating stuffy nose. The three medicines are used together to open qi stagnation, ventilate lung and nose orifices, clear head and eyes, and cooperate with Qiang Huo to ventilate qi and promote nose orifices, which is a ministerial medicine. Chiral flavor is pungent, bitter, sour and warm. Has effects in dispersing stagnated liver qi and regulating qi-flowing. Clove is pungent and warm in nature, and can warm the middle-jiao, check adverse rise of qi, tonify kidney and strengthen yang. The two herbs are used together to warm yang, transform qi, move qi and resolve dampness, so as to make nasal orifices have no dampness obstruction and nasal discharge. The rhizoma ligustici wallichii, pungent and warm in property, can activate blood and promote qi circulation, dispel wind and relieve pain, can relieve nasal obstruction and vein obstruction and regulate qi and fluid to move when being used as an adjuvant drug. The whole formula is designed for regulating qi, blood and body fluid of nasal orifices, and is used for expelling pathogenic factors, promoting qi circulation, activating blood and eliminating dampness, and lung qi can be dispersed and descended when qi, blood and body fluid normally run, so that nasal discharge is stopped and nasal orifices are unobstructed.

Experimental results show that the rhinitis ointment prepared by using the pharmaceutical composition as an active ingredient can effectively relieve symptoms such as sneezing, nasal obstruction, watery nasal discharge and the like caused by allergic rhinitis, acute and chronic rhinitis, nasosinusitis and cold, and the treatment effect is obviously better than that of normal saline. Compared with the existing nasal spray, the rhinitis ointment prepared by the invention does not contain jute extract or hormone substances, has small toxic and side effects and stable long-term curative effect, and can not cause rhinitis rebound (such as more serious nasal obstruction); moreover, the rhinitis ointment can play a slow release role for a long time by being smeared around the nasal cavity and the nasal wings, and achieves a percutaneous absorption effect, thereby playing a drug effect and obviously improving the acceptance degree of patients.

The pharmaceutical composition provided by the invention is taken as an active ingredient, and auxiliary materials which are acceptable in pharmacy or commonly used in the daily chemical field are added, so that the medicine or daily chemical product for treating rhinitis and symptoms such as sneeze, nasal obstruction, rhinorrhea and the like caused by rhinitis can be prepared, and the application prospect is wide.

Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.

The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.

Detailed Description

The raw materials and equipment used in the invention are known products and are obtained by purchasing commercial products.